Ann D’Hondt

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Communicative abilities in young children with a significant cognitive and motor developmental delay

Ann D’Hondt, Ines Van keer, Annette van der Putten et al. · Journal of Applied Research in Intellectual Disabilities · 2019 · 46 citations · Full text

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures

Pieternel Vanherpe, Steffen Fieuws, Ann D’Hondt et al. · Orphanet Journal of Rare Diseases · 2020 · 36 citations · Full text

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Hiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki et al. · Journal of the Neurological Sciences · 2019 · 23 citations · Full text

Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study

Philip Van Damme, Petra Tilkin, Katarina Jansson Mercer et al. · Brain Communications · 2020 · 20 citations · Full text